EMA Public Support for Mobilise-D

In the first year of Mobilise-D, we asked the European Medicines Agency (EMA) for qualification advice for Digital Mobility Outcomes (DMOs). EMA just published their letter of support that publicly endorses our initial stage in the wider objective of the Mobilise-D Consortium to pursue the qualification of Digital Mobility Outcomes (DMOs) as monitoring biomarkers of mobility performance in regulatory drug trials. We have now got support to continue our work towards regulatory approval of DMOs as biomarkers! You can read the full letter of support here.